Detection of serum protein and circulating mRNA of cMET,HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy

Abstract

BACKGROUND:

Reseptor tyrosine kinases (cMET and EGFR) are important in lung cancer targeted therapy. We believe if we can use them as markers for clinicians to help decide the diagnosis of lung cancer. This parameter will be important in serum samples of patients with lung cancer diagnosis and treatment. The aim of this study is aimed to evaluate the clinical utility of serum protein and circulating mRNA of cMET and HGF in lung cancer patients. We also analyzed the correlation of mRNA expression with clinicopathologic parameters.

METHODS:

We performed enzyme-linked immunosorbent assay (ELISA) to measure and compare serum protein and circulating mRNA of cMET and HGF levels in peripheral blood from 60 lung cancer patients and 40 healthy control group.

RESULTS:

We found that both protein and gene expression levels of serum c-MET, HGF and EGFR were significantly higher in patients with lung cancer than control group. There was no association between HGF, cMET, EGF, EGFR (both protein and gene) expression levels with age, gender, smoking habit, COPD, pathological types or tumor size, stage, metastatic-non metastatic adenocarcinoma-squamous carcinoma, SCLC-NSCLC. As a result of ROC analysis, serum cMET (AUC: 0.892) and HGF protein (AUC: 0.784) were diagnosed in lung cancer patients (Fig. 1). The AUC values of serum EGF and EGFR proteins were calculated to be 0.631 and 0.692, respectively.

CONCLUSION:

To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients’ blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies.

Keywords

Reseptor tyrosine kinases growth factors lung cancer

1. Introduction

Lung cancer is the second most commonly diagnosed cancer worldwide. It is also the leading cause of cancer mortality among men and women. Despite developments in both diagnosis and therapeutic strategies of lung cancer, 5 year survival rate in tumors that are not mutation-driven still doesn’t exceed 20% [1].

Because of its high frequency and high mortality rate, early detection is exteremely important in order to improve the outcome. Lung cancer screening has been a trend debated topic since 1990’s. Many recent studies have focused on the development of a specific, sensitive, convenient and non-invasive techniques, such as circulating biomarkers to detect lung cancer at an earlier stage. Recently, the presence of circulating tumor-specific nucleicacids (cNA) has been validated in plasma, serum, and other body fluids from different type of cancer patients and they have been proposed as a noninvasive source of tumor-derived information.

In addition to DNA, circulating RNA is detectable through its ability escaping from degradation in the blood [2]. This stability is partially explained by the discovery that the circulating RNA is included within small membrane vesicles, i.e. exosomes, which protect the RNA from ribonucleases (RNases) [3]. As deregulated RNA expression is an early event in tumorigenesis and tumor progression, the measurement of circulating RNA might also be useful for early cancer detection and prognosis. Altough there are limited data on the clinical role of cRNA in lung cancer, recently, some studies have been investigated the role of circulating mRNAs of cMET HGF and EGFR EGF in diagnostic and prognostic evaluation of lung cancer.

The aim of this study is aimed to evaluate the clinical utility of serum protein and circulating mRNA of cMET and HGF in lung cancer patients. We also analyzed the correlation of mRNA expression with clinicopathologic parameters.

2. Material and methods

Sixty patients who were diagnosed with lung cancer and treated at Istanbul University Oncology Institute between January 2015 to January 2016 were included in this retrospective study.

Serum serum protein and circulating mRNA of cMET and HGF levels were studied with ELISA in both the patient group and the control group which consisted of 20 healthy volunteers.

Our study on human materials has been approved by the Istanbul University Ethics Committee. The protocol was consistent with the Declaration of Helsinki (1989). Informed consent was obtained from all study participants.

Blood samples of the patients and control group were obtained by venipuncture and clotted at room temperature. The sera were collected following centrifugation and frozen immediately at $-$ 80 ${}^{\circ}$ C until use. Serum samples were obtained on first admission before any adjuvant and metastatic treatment was given or follow-up patients. Blood samples were obtained from patients and healthy controls by venipuncture and clotted at room temperature. The sera were collected following centrifugation (10 min 4000 rpm) at room temperature and frozen immediately at $-$ 20 ${}^{\circ}$ C until analysis.

2.1 Measurement of serum cMET HGF EGFR EGF levels

A double-antibody sandwich ELISA was used to determine the level of Neural precursor cell expressed developmentally down-regulated protein cMET (Shanghaıyehua biological technology Co, Ltd) in the samples. Serum samples and standards were added to the wells, which were pre-coated with human cMET monoclonal antibody; streptavidin-horseradish peroxidase conjugate was added to form an immune complex and allowed to incubate at 37 ${}^{\circ}$ C for 1 h. Unbound material was washed away. Chromogen solution was added and incubated at 37 ${}^{\circ}$ C for 10 min (protected from light) for the conversion of the colorless solution to a blue solution, the intensity of which was proportional to the amount of cMET in the sample. Under the effect of the acidic stop solution, the color turned to yellow and the colored reaction product was measured using an automated ELISA microplate reader (ChroMate ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ 4300; awareness technology) at 450 nm. This method is also used for HGF EGFR and EGF.

2.2 Quantification of cMET/HGF EGFR/EGF mRNA in serum

For analyzing cMET and HGF EGFR and EGF specific mRNA in sera of the patients, circulating cell-free RNA was extracted from serum using a monophasic phenol and guanidine thiocyanate solution (Roche, Mannheim, Germany) according to the manufacturer’s protocol. Briefly, 200 $\mu$ l of sera are added on 800 $\mu$ l of RNA isolation solution and 200- $\mu$ l chloroform are added and mixed. Following incubation on ice for 5 minutes, the mixture is centrifuged at 11,000 rpm for 15 minutes at 4 ${}^{\circ}$ C. The RNA phase is transferred into a fresh tube containing 550- $\mu$ l propanol. The mixture is centrifuged again at 11,000 rpm for 10 minutes at 4 ${}^{\circ}$ C.

The pellet containing RNA is washed with 75% alcohol, dried at RT, and dissolved in 20 $\mu$ l RNase-free water. cDNAwas synthesized using a commercial kit (Roche, Mannheim, Germany) according to instructions of the manufacturer.

cMET and HGF; EGFR and EGF gen expression in serum was quantified semiquantitatively using GAPDH as the internal control and SYBR Green (Roche Mannheim, Germany) as the fluorescence mol- ecule.

Real-time PCR was performed in the LightCycler 480 Instrument (Roche, Mannheim, Germany). The reaction conditions included a hot start of 10 minutes at 95 ${}^{\circ}$ C and 45 cycles of amplification consisting of denaturation at 95 ${}^{\circ}$ C for 30 seconds, annealing at 59 ${}^{\circ}$ C for 30 seconds, and extension at 72 ${}^{\circ}$ C for 1 second. We used exon-spanning specific primers designed using the Universal Probe Library software (Roche, Mannheim, Germany). Amplification of the appropriate product for each molecule was confirmed by melting curve analysis. Expression levels of each RNA are originally presented as the threshold cycle (Ct) values, defined as the fractional cycle number at which the fluorescent signal exceeds the fixed threshold in qRT-PCR. For data analysis, we used the comparative Ct method, normalized by subtracting the Ct value of endogenous reference from each RNA. Two independent real-time PCR experiments were performed to calculate the average values.

Table 1
Patient characteristics and disease status

	N	%
No. of patients	60	100
Age of patients 60 (35–77)
$-$ 60	31	51.7
60 $+$	29	48.3
Gender male/female	51/9	85/15
Histology
NSCLC	50	83.3
Adenocarcinoma	28	56
Squamous cell	20	40
Undifferentiated	2	4
SCLC	10	16.7

2.3 Statistical analysis

SPSS for Windows version 18.0 (SPSS Inc. Chicago, IL, USA) was employed for data analysis. Continuous variables were categorized using median values as cutoff point. Assessment of relationships, comparisons between various clinical/laboratory parameters were accomplished using Mann-Whitney U test and Kruskal-Wallis test for two and three groups, respectively. Spearman’s rank order correlation was used for correlation analysis. $p$ values $\leqslant$ 0.05 were considered statistically significant. AUC (Area Under Curve) was determined using ROC (Receiver Operating Characteristic) curve.

3. Results

Table 1 summarizes the histopathological characteristics, demographic features of 60 lung cancer patients diagnosed with lung cancer who were treated at Istanbul University Oncology Institute From January 2015 to January 2016.

Table 2
Levels of serum protein levels in the lung cancer patients and healthy controls

	Lung cancer	Control	$p$ value
Levels of	( $n=$ 60)	( $n=$ 20)
protein	x $\pm$ sd	x $\pm$ sd
	$m(\min,\max)$	$m(\min,\max)$
HGF (ng/L)	1163.3 $\pm$ 787.2	570.1 $\pm$ 845.5
	872.5 (351.8–3811.2)	355.5 (78.4–3963.0)	0.000
cMET	387.6 $\pm$ 259.2	229.5 $\pm$ 168.6
(ng/L)	251.7 (68.3–1054.5)	180.5 (68.4–739.2)	0.002
EGF (ng/L)	667.0 $\pm$ 417.9	465.3 $\pm$ 172.2
	526.2 (125.8–2141.2)	479.2 (304–706.6)	0.181
EGFR	41.302 $\pm$ 23.6	34.1 $\pm$ 6.7
(ng/mL)	31.5 (17.4–138.6)	28.5 (22.6–45.8)	0.09

Figure 1.

ROC curves of cMET and HGF.

We analyzed circulating cell-free RNA to mesure cMET and HGF EGFR and EGF specific mRNA in the blood serum in 60 patients and 40 healthy controls to determine the role of cRNA as a tumor marker new anticancer targeted therapies for lung cancer. Serum protein HGF levels were significantly higher in patients with lung cancer (872.5 ng/L) as compared to healthy individuals (355.5 ng/L) ( $p=$ 0.00). Serum protein CMET levels were significantly higher in patients with lung cancer (251.7 ng/L) than healthy control group (180.5 ng/L) ( $p=$ 0.002) (Table 2, Fig. 1).

Table 3

Levels of serum gen expression levels in the lung cancer patients and healthy controls

	Lung cancer	Control	$p$ value
Levels of	( $n=$ 60)	( $n=$ 20)
gen	x $\pm$ sd	x $\pm$ sd
expression	$m(\min,\max)$	$m(\min,\max)$
HGF	0.62 $\pm$ 1.54	0.019 $\pm$ 0.022
	0.24 (0.0–10.81)	0.086 (0.001–0.082)	0.000
cMET	2.3 $\pm$ 5.16	0.066 $\pm$ 0.90
	0.38 (0.00–22.68)	0.032 (0.012–0.38)	0.000
EGF	0.026 $\pm$ 0.074	0.0032 $\pm$ 0.0319
	0.0048 (0.0–0.38)	0.0015 (0.002–0.0088)	0.196
EGFR	0.072 $\pm$ 0.173	0.0052 $\pm$ 0.0114
	0.0064 (0.0–0.98)	0.0007 (0.0–0.044)	0.018

Figure 2.

ROC curves of EGF and EGFR.

Table 4

Results of comparisons between serum Cmet, HGF, EGFR, EGF protein and various demographic and disease

	Number of	Median	$P$ value	Median	$P$ value	Median	$P$ value	Median	$P$ value
	patients	Cmet ()		HGF		EGFR		EGF
Age
$<$ 60	31	303.0	0.469	891.7	0.965	31.0	0.819	498.4	0.294
$>$ 60	29	234.4		858.1		31.9		537.5
Smoking
Yes	40	360.5	0.325	756.2	0.910	29.8	0.926	526.8	0.914
No	20	301.2		700.4		30.5		512.4
Gender
Male	51	244.6	0.535	858.1	0.583	31.9	0.812	529.0	0.336
Female	9	355.0		944.4		29.9		498.4
Stage
Early	2	399.1	0.667	1657.5	0.367	43.5	0.888	883.5	0.647
Advanced	58	256.8		1542.2		40.5		784.2
Metastasis
Yes	32	256.8	0.778	868.4	0.965	31.1	0.912	522.9	0.947
No	28	239.1		874.7		32.3		541.7
Histological
NSCLC	50	311.3	0.052	849.2	0.905	31.6	0.579	526.2	0.736
SCLC	10	217.6		891.7		31.2		511.9
Type
Adeno	30	277.0	0.255	894.9	0.469	31.4	0.888	509.1	0.647
Squamoz	30	248.5		826.2		31.6		533.2

Figure 3.

cMET-EGFR correlation.

Table 5

Results of comparisons between serum Cmet, HGF, EGFR, EGF gen and various demographic and disease

	Number of	Median	$P$ value	Median	$P$ value	Median	$P$ value	Median	$P$ value
	patients	Cmet ()		HGF		EGFR		EGF
Age
$<$ 60	31	0.301	0.784	0.183	0.529	0.0046	0.399	0.0046	0.415
$>$ 60	29	0.404		0.342		0.0068		0.0069
Smoking
Yes	40	0.311		0.256		0.326		0.145
No	20	0.304		0.147		0.215		0.124
Gender
Male	51	0.301	0.153	0.260	0.605	0.054	0.648	0.054	0.950
Female	9	0.771		0.174		0.068		0.046
Stage
Early		1.234	0.545	0.521	0.606	0.180	0.667	0.0029	0.667
Advanced		0.890		0.153		0.004		0.0073
Metastasis
Yes	32	0.427	0.328	0.235	0.684	0.041	0.324	0.051	0.841
No	28	0.229		0.221		0.073		0.046
Histological
NSCLC	50	0.404	0.699	0.196	0.613	0.0066	0.311	0.0063	0.066
SCLC	10	0.253		0.301		0.0022		0.0018
Type
Adeno	30	0.476	0.647	0.182	0.234	0.041	0.321	0.0045	0.941
Squamoz	30	0.334		0.310		0.082		0.0068

Serum protein EGF levels were not istatistically higher in patients with lung cancer than healthy control group ( $p=$ 0.181). Serum protein EGFR levels were significantly higher in patients with lung cancer (31.5 ng/mL) than healthy control group (28.5 ng/mL) ( $p=$ 0.09) (Table 2).

HGF gene expression levels in lung cancer patients were higher than healthy control group and statistically significant ( $p=$ 0.00). In lung cancer patients, cMET gene expression levels were found to be statistically higher than healthy controls ( $p=$ 0.000). There were no significant difference between EGF expression lung cancer patients and contol group ( $p=$ 0,196). EGFR gene expression levels in lung cancer patients (0.0064) were also istatistically higher than the healthy control group (0.0007) ( $p=$ 0.018) (Table 3, Fig. 2).

The correlation between HGF, cMET, EGF, EGFR at both protein and gene expression levels and clinicopathological characteristics of the patient group is shown in Table 3. There was no association between HGF, cMET, EGF, EGFR (both protein and gene) expression levels with age, gender, smoking habit, COPD, pathological types or tumor size, stage, metastatic-non metastatic adenocarcinoma-squamous carcinoma, SCLC-NSCLC (Tables 4 and 5).

ROC analysis of each test was performed. AUC (Area under Curve) was calculated according to ROC curves. As a result of ROC analysis, serum cMET (AUC: 0.892) and HGF protein (AUC: 0.784) were diagnosed in lung cancer patients (Fig. 1). The AUC values of serum EGF and EGFR proteins were calculated to be 0.631 and 0.692, respectively (Fig. 2). According to AUC, the diagnostic value of cMET and HGF was higher than EGF and EGFR.

4. Discussion

Oncoproteins that bind to proteins in the pathway to which protein kinase receptors associated with growth factors are attached block or modify the effects of growth factors. Among the important members of these oncoproteins are c-MET. Oncogenes such as c-MET lead to overproduction of growth factor genes and cause excessive release of the hepatocyte growth factor. Cancer occurs as a result of the altered growth signal [4].

Because of its early invasion and spread to distant organ potential, early detection is extremely important. In order to improve the outcome it is very important to detect these cells early in lung cancer. The fact that c-MET mediated tyrosine kinase signal transduction leads to an excessive increase in oncogenes; it is one of the most remarkable topics today. In recent years, a great deal of information has been obtained about the normal structural properties and biological functions of c-MET. c-MET and HGF have been shown to increase expression in many cancers, including NSCLC [5]. In our study, the expression levels of HGF and c-MET in lung cancer patients were also found to increase which is compatible with the literature.

c-MET pathway activation triggers a program similar to in vivo tumor metastasis that begins with increased cell motility, progressive cell invasion and angiogenesis enhancement by extracellular matrix degradation along with protease production. It is known that HGF changes the migration and invasion capacities of cancer cells by increasing the secretion/expression of cancer cells from matrix and endothelial adhesion and photolytic enzymes [6]. All of these features are thought to be important for invasive phenotype acquisition of the tumor [7].

The developments in molecular biology of lung cancer for the last 10 years and the use of specially targeted agents have been changed the treatment approach. The role of the EGFR receptor in the treatment of lung cancer has been investigated in the majority of EGFR inhibitors, given both the pathogenesis location of the EGF receptor in cancer biology and its role in tumor development [9]. EGFR inhibitor agents block the tyrosine kinase activity of EGFR, which is highly up-regulated in NSCLC, resulting in inhibition of cell activation and proliferation.

Masroor et al. found that EGFR gene expression was 13.5 fold higher in NSCLC than in normal controls and in healthy controls when they performed RT-PCR on serum mRNAs [8]. In this study, which is similar to our study as material and method used, statistical significance was found between NSCLC and healthy control ( $p<$ 0.001). In our study, high EGFR expression levels were also found significantly higher than control group in patient group ( $p=$ 0.018).

Studies about targeted cytokine tyrosine kinase activity in lung cancer are ongoing. c-MET oncogene is a high affinity receptor for HGF. Genetic mutation and gene amplification in c-MET is very common in many cancer types. Over expression of c-MET has also been shown in cases of lung, stomach, liver, and colorectal cancer and is associated with poor prognosis [10]. HGF found in plasma and synthesized from platelets, plays a major role in liver regeneration. It is also detected at a very low level in the normal lung. It induces budding and branching in the embryonic lung. There are some studies showing increased expression of HGF in lung cancer. Consistent with previous data, in our study, we also found significant association with high HGF protein and gene expression levels in NSCLC patients group than control group (respectively 1163.3 $\pm$ 787.2 ng/L &570.1 $\pm$ 845.5 ng/L; 0.62 $\pm$ 1.54 & 0.019 $\pm$ 0.022). These results suggest that HGF is budding or hyper branched, just as it is in the embryonic lung.

Previous studies demonstrate significant correlation between c-MET and EGFR expressions [11]. In our study there is a significant correlation between c-MET and EGFR expressions in serum samples (Fig. 3, $r=$ 0.60). This data is important data for individual theraby. These two molecules carry tyrosine kinase receptor feature, which can be targeted in lung cancer treatments with tyrosine kinase activity.

Cheng et al. conducted a study with 45 lung cancer patients. They found that c-MET mRNA levels both in tumor tissue and peripheral blood were significantly high in lung cancer ( $p=$ 0.016) [12]. In our study, c-MET mRNA levels in lung cancer patients serum material were found to be significantly higher than control group ( $p=$ 0.00).

Blumenschein and friends did not find statistical significance between the histological sub parameters of serum HGF levels ( $P>$ 0.05) [13] with ELISA between (79 adenocarcinoma and 26 squamous cell carcinoma diagnosed patients. In this study we also did not find statistical significance between histological types in serum HGF levels ( $p>$ 0.05) (Tables 4 and 5).

This suggests that HGF is a biomarker that can be used clinically in patients with lung cancer, even if histological types are different.

Expression of HGF and its receptor c-MET has been reported to be increased in lung, colon, breast, thyroid, renal carcinoma, melanoma and various sarcomas. Several studies have shown that HGF plays a role in tumor progression. The binding of HGF to c-MET results in the phosphorylation of intracellular tyrosine segments of c-MET. In general, HGF is involved in invasion and metastatic processes in the development and progression of many cancers through its receptor c-MET. While HGF has been reported to play a role in the early stages of cancer, investigations are still underway for reliable and robust evidence in this regard [14]. In the light of these findings, it is reported that C-MET may be one of the oncogenes controlling the metastasis progression of primary cancers. Invasion and metastasis processes of lung cancers are thought to be related to the activation of the motile vacuoles involved in the HGF/c-MET signaling pathway [15]. This hypothesis has guided us to plan our study.

Studies targeting growth factors in lung cancer treatments address the issue of establishing diagnostic or prognostic markers that depend on the amount of these molecules and blocking signal transduction molecules or signaling pathways activated by these signaling molecules in localized tissues [16]. In our study based on this prediction, we determined the relationship between gene expression and protein by determining both protein levels of EGFR/EGF and c-MET/HGF and mRNA levels of these two signaling pathways involved in lung cancer.

Genetic changes in the EGFR and c-MET genes play an important role in the development of lung cancer. Changes in these genes cause cancer to become more aggressive. We think that increasing the number of studies to determine how changes in EGFR/EGF and c-MET/HGF genes play a role in the development of cancer and determining the treatment strategies to be created will provide important contributions to the clinicians in the slowing or stopping cancer progression.

The presence of HGF molecules circulating freely in lung cancer patients in the selection of HGF/c-MET signaling pathway based target therapies showed that c-MET and HGF could be used as useful biomarkers. In our study, when ROC curves of each test were examined, c-MET (AUC: 0.892) and HGF a visible reference line curve by the extent to which it is observed that the diagnostic value and above. On the other hand, EGF (0.631) and EGFR (0.692) concluded that the diagnostic value according to the curve of AUC calculation result is lower than the c-MET and HGF.

To summarize, lung cancer development is based on highly complex molecular pathways. Several novel biomarker molecules are identified (by several molecular techniques such as FISH and RT-PCR) and their role in cancer development is being investigated. In our study, the relationship between gene expression levels measured by RT-PCR and protein levels determined by ELISA was investigated.

Today, tumor tissues from lung cancer patients are pathologically examined together with clinical findings. After that, mutation analysis is performed by searching whether EGFR pathway is used to plan individualized treatment. If the paraffin block section of tumor tissue is not sufficient, it is not possible to plan treatment for the individual.

5. Conclusion

To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients’ blood samples. We found that both protein and gene expression levels of serum cMET, HGF and EGFR were higher in patients with lung cancer. We suggest that protein and gene expression levels of c-MET in patients with lung cancer will lead to targeted therapies as a new biomarker.

Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of biomarkers to show early response and resistance of c-MET in targeted therapies.

Footnotes

Acknowledgments

All the co-authors have responded to the verification of authorship request. The present work was supported by the Research Fund of Istanbul University. Project No. 6291.

Conflict of interest

The authors declare no confict of interest.

References

Alyson

Mark

Thornquist

E.W.

Emily

Lisa

A.J.

Garry

E.G.

and Thomas

L.V.

, Prior lung disease and risk of lung cancer in a large prospective study, Cancer Causes and Control 819 (2004), 819–827.

Johnson

P.J.

and Lo

Y.M.

, Plasma nucleic acids in the diagnosis and management of malignant disease, Clin Chem 48 (2002), 1186–1193.

Peter

B.G.

, Circulating nucleic acids in plasma and serum: Diagnosis and prognosis in cancer, EPMA Journal 1 (2010), 503–512.

Sacher

A.G.

L.W.

Lara-Guerra

Waddell

T.K.

Sakashita

Chen

et al., A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer, Oncotarget (25 Mar 2016).

Lorenzato

Olivero

Patanè

et al., Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion, Cancer Res 62(23) (2002), 7025–7030.

Birchmeier

Gherard

E.V.

and Woude

G.F.

, Met, metastasis motility and more, Nature Reviews Molecular Cell Biology 4 (2003), 915–925.

Kitajo

Shibata

and Nagayasu

, Rho regulates the hepatocyte growth factor/scatter factor-stimulated cell motility of human oral squamous cell carcinoma cells, Oncol Rep 10(5) (2003), 1351–1356.

Masroor

Mir

Javid

Prasant

Imtiyaz

Mariyam

et al., Cell free EGFR mRNA expression and implications for survival and metastasis in non-small cell lung cancer cases, Asian Pac J Cancer Prev 16(15) (2015), 6445–6449.

Martin

Kelly

C.M.A.

and Carney

, Epidermal growth factor receptor-targeted agents for lung cancer, Cancer Control 13(2) (2006), 129–140.

10.

Organ

S.L.

and Tsao

M.S.

, An overview of the c-MET signaling pathway, Ther Adv Med Oncol 3(1 Suppl) (Nov 2011), S7–S19.

11.

Van Der Steen

Pauwels

Gil-Bazo

Eduardo

C.L.R.

Federico

et al., cMET in NSCLC: Can we cut off the head of the hydra? from the pathway to the resistance, Cancers (Basel) 7(2) (25 Mar 2015), 556–573.

12.

Cheng

T.L.

Chang

M.Y.

Huang

C.C.

Sheu

S.Y.

Kao

E.L.

Cheng

Y.J.

et al., Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer, Chest 128(3) (Sep 2005), 1453–1460.

13.

Blumenschein

G.R.

, Jr. Mills

G.B.

and Gonzalez-Angulo

A.M.

, Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy, J Clin Oncol 30(26) (10 Sep 2012), 3287–3296.

14.

Ujiie

Tomida

Akiyama

Nakajima

Okada

Yoshino

et al., Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer, Anticancer Res 32(8) (Aug 2012), 3251–3258.

15.

Zucali

M.G.

Ruiz

Giovannetti

D.A.

Varella-Garcia

Floor

et al., Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors, Annals of Oncology 19 (2008), 1605–1612.

16.

Seiji

Yasuhiko

Hisatsugu

and Saburo

, Molecular mechanisms of angiogenesis in non-small cell lung cancer and therapeutics targeting related molecules, Cancer Sci June 94(6) (2003), 479–485.